Teva Seeks To Simplify With Canadian Inhalers
Launches Innovative Inhalation Device With ‘Price Advantage’
Teva’s innovative asthma device, Aermony RespiClick (fluticasone propionate inhalation powder), will be accessible to over 3.8 million affected asthmatic patients in Canada in three dose options.
You may also be interested in...
Teva has completed its portfolio of digital inhalers by launching a further two products, AirDuo Digihaler (fluticasone propionate/salmeterol) and ArmonAir Digihaler (fluticasone propionate), in the US. The pair join the firm’s previously launched ProAir Digihaler (albuterol sulfate).
The FDA has revealed details of its recent warning letter to Shilpa, which cites the company’s failure to adequately investigate out-of-specification results and complaints as well as to follow written procedures for complaint handling.
Pfizer has reported 80% growth in its global biosimilars business for the third quarter of 2020, on the back of recent oncology launches. Though the company’s sterile injectables saw a slight drop in business, Pfizer’s biopharma business saw 4% growth.